Introduction
Parkinson's disease (PD) is characterized by several pathological hallmarks such as the relatively selective degeneration of nigral dopaminergic (DA) neurons, intracellular inclusions (Lewy bodies) and dystrophic processes (Lewy neurites) (Lang and Lozano, 1998) . Long-term epidemiological studies, especially those performed on twins, strongly suggest that environmental toxins play a critical role in the common, late-onset forms of PD (Tanner et al., 1999; Langston, 2002) . It has been shown recently that systemic administration of rotenone, a naturally occurring substance widely used as a pesticide, produces specific degeneration of nigral DA neurons and PD-like locomotor symptoms in rats (Betarbet et al., 2000) .
Rotenone acts directly on two targets in the cell; it inhibits complex I in the mitochondrial respiratory chain (Chance et al., 1963) and depolymerizes microtubules (Marshall and Himes, 1978) . Our previous study has shown that the microtubuledepolymerizing activity of rotenone is critical in determining its selective toxicity on DA neurons (Ren et al., 2005) . Microtubule depolymerization disrupts vesicular transport, which leads to accumulation of vesicles in the soma. In dopaminergic neurons, leakage of dopamine from the vesicles greatly increases oxidative stress induced by DA oxidation, which triggers cell death (Ren et al., 2005) . Consistent with these results, defects in microtubulebased transport have been shown to play a major role in many neurodegenerative disorders (Goldstein, 2003) . Thus, microtubule dysfunction is not only critically involved in neurodegeneration, it may also provide a unique cellular mechanism that leads to the death of specific neuronal population. Enhancing microtubule stability would offer a novel approach to protect against environmental PD toxins such as rotenone.
Metabotropic glutamate receptors (mGluRs) are a group of G-protein-coupled receptors (GPCRs) for glutamate. Based on their sequence homology, signal transduction, and pharmacological profiles, eight different mGluR genes are classified into three subfamilies (Conn and Pin, 1997) . Group I metabotropic glutamate receptors (mGluRI) include mGluR1 and mGluR5, which couple to the G q or G o class of G-proteins to activate phospholipase C (PLC). Group II mGluRs (mGluRII) consist of mGluR2 and mGluR3, which inhibit adenylyl cyclase by activating G i . Group III mGluRs (mGluRIII) comprise mGluR4, mGluR6, mGluR7, and mGluR8, which also inhibit adenylyl cyclase through G i . The unique expression pattern and subcellular localization of different mGluR enables them to perform very specific functions in the brain (Conn, 2003) . For example, various mGluRs are differentially expressed in basal ganglia and play critical roles in modulating neuronal activities in the motor circuits that are severely affected in Parkinson's disease (Rouse et al., 2000; Conn et al., 2005) . On the other hand, increasing evidence has suggested that mGluRs have diverse neuroprotective functions (Nicoletti et al., 1996; Flor et al., 2002) . For instance, activation of mGluRIII attenuates excitotoxic neuronal death (Bruno et al., 2000) , hypoxic/hypoglycemic neuronal damages (Sabelhaus et al., 2000) , and A␤ toxicity (Copani et al., 1995) . In the present study, we show that mGluRIII agonists attenuated rotenone toxicity on TH ϩ neurons in midbrain neuronal cultures by activating the microtubule-associated protein (MAP) kinase pathway to stabilize microtubules.
Materials and Methods
Antibodies. Rabbit polyclonal antibodies against extracellular signalregulated kinase 1/2 (ERK1/2) and Thr 202 /Tyr 204 phosphorylated ERK1/2 were purchased from Cell Signaling (Beverly, MA). A rabbit antibody against Tyr 418 phosphorylated Src was purchased from Biosource (Camarillo, CA). Rabbit anti-TH was from Affinity BioReagents (Golden, CO). Mouse anti-NeuN was from Chemicon (Temecula, CA). Mouse anti-HA was from Roche (Nutley, NJ). Mouse anti-␣-tubulin was from Sigma (St. Louis, MO). Mouse anti-␤-arrestin 1 was from BD Biosciences (San Jose, CA). Mouse anti-␤-arrestin 2 and rabbit anti-c-Src were from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-MAP2 was from Upstate Biotechnology (Lake Placid, NY). Alexa Fluor 488-conjugated anti-rabbit IgG and Alexa Fluor 594-conjugated antimouse were purchased from Invitrogen (Carlsbad, CA).
Preparation of midbrain cultures. All reagents were from were Invitrogen unless otherwise specified. Midbrain neuronal cultures were prepared from embryonic day 17 fetuses of pregnant Sprague Dawley rats (Harlan, Indianapolis, IN) as described previously (Ren et al., 2005) , with minor modifications. Briefly, ventral mesencephalons were meticulously dissected and freed of meninges in ice-cold DMEM. Midbrain cells were dissociated by digestion in 0.25% trypsin-EDTA for 30 min at 37°C and subsequent addition of DNaseI (Roche) to a final concentration of 0.1 mg/ml. Cells were then incubated at room temperature for another 5 min, followed by addition of seeding medium (DMEM supplemented with 10% fetal bovine serum) and gentle trituration. After the cells were pelleted at 200 g for 5 min, they were resuspended in seeding medium and seeded onto poly-D-lysine-coated (Sigma) wells or coverslips in multiwell plates at a density of 0.5-2 ϫ 10 5 cells/cm 2 . Cultures were incubated at 37°C in 5% CO 2 and maintained in Neurobasal medium supplemented with B-27 and 0.5 mM glutamine. Cytosine arabinoside (2.5 M) was added to culture media from the fourth day to inhibit glia growth and the medium was half changed every 4 -5 d.
Drug treatments. and 4-amino-7-phenylpyrazol[3,4- 
chromen-1a-carboxylate ethyl ester (CPCCOEt), 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP), (2S)-␣-ethylglutamic acid (EGLU), (RS)-1-amino-5-phosphonoindan-1-carboxylic acid (APICA), NMDA, AMPA, Gln-Val-Pro-SerArg-Pro-Asn-Arg-Ala-Pro (dynamin inhibitory peptide, P4), and myristoylated P4 (myr-P4) were obtained from Tocris (Ellisville, MO). All drugs were made as 1000ϫ stocks in water, except for L-AP-4 and CPPG, which were made as 1000ϫ stocks in 0.1N NaOH, and PP1, PP2, and PP3, which were made as 1000ϫ stocks in DMSO (Sigma). All 1000ϫ stocks were diluted to 10ϫ stocks with culture medium immediately before addition to the neuronal cultures, which were maintained in vitro for 14 d. All inhibitors were added 30 min before the primary treatment and were present for the whole duration of the primary treatment.
Transfection of SiRNA or plasmid DNA. Double-stranded small interfering RNA (siRNA) targeting rat ␤-arrestin 1 (NM_012910) and ␤-arrestin 2 (NM_012911) were purchased from Ambion (Austin, TX). Their sequences are 5Ј-GGCGAGUCUACGUGACACUtt-3Ј and 5Ј-GGACCGGAASGUGUUUGUGtt-3Ј, respectively. Plasmid constructs for HA-tagged wild-type MAP kinase kinase (MEK) 1 (wt-MEK) and dominant-negative MEK1 (dn-MEK) (K97M mutant) were described previously (Yuen et al., 2005) . At 10 -12 d in vitro, midbrain neuronal cultures were transfected with 1 g of siRNA per 3.5 cm dish or transfected with 1.6 g of plasmid DNA per well in 12-well plates, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Subsequent treatments were performed 48 h after transfection.
Preparation of cell extracts. For each treatment, one 3.5 cm dish that was initially seeded with 2 ϫ 10 5 /cm 2 midbrain neurons was washed three times with PBS. The culture was lysed in cold-buffer T (1% Triton X-100, 10 mM Tris, pH 7.6, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 5 mM EDTA, and 0.1 mM Na 3 VO 4 ) for 20 min on ice. The lysates were centrifuged at 4°C at 16,000 ϫ g for 20 min, and the supernatant was analyzed by Western blotting. Subcellular fractionation studies were performed as described previously (Wong et al., 2002) , with minor modifications. Briefly, PBS-washed neuronal cultures were harvested by scraping in 200 l cold-buffer A (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM MgCl 2 , 0.1 mM EDTA, 15% glycerol, 0.1 mM Na 3 VO 4 , 50 mM NaF, 1 mM DTT, 0.5 mM PMSF, and protease inhibitors). Cell lysates were incubated on ice for 10 min with gentle shaking. After 5 min spin at 200 ϫ g at 4°C, supernatant S1 and precipitant P1 were collected. S1 was centrifuged at 16,000 ϫg for 15 min and the supernatant S2 was used as the cytosol cell extract. P1 was suspended in 100 l ice-cold buffer B (10 mM HEPES, pH 7.4, 10 mM KCL, 1 mM MgCl 2 , 0.1 mM Na 3 VO 4 , 50 mM NaF, 0.1% NP40, 1 mM DTT, 0.5 mM PMSF, and protease inhibitors) and incubated on ice for 30 min with gentle shaking. Then the suspension was centrifuged for 15 min at 16,000 ϫg at 4°C, and supernatant S3 was saved as the nuclear cell extract. In parallel experiments, cultured neurons were washed thrice in PBS, scraped off the plate and lysed in 200 l 1% hot SDS with glass homogenizer in a boiling water bath. After the lysate was centrifuged at 16,000 ϫg for 15 min, the supernatant was used as the total cell lysate.
Immunocytochemistry and quantification of cell death. Immunocytochemistry was performed as described previously (Ren et al., 2003) , with minor modifications. After drug treatments, cells growing on coverslips were fixed in 4% PFA for 20 min at room temperature, followed by three washes in PBS, 15 min permeabilization in 0.1% Triton X-100 in PBS, and 1 h incubation with 3% BSA in PBS. Subsequently, cells were incubated with primary antibodies for 2 h at room temperature and then for 16 h at 4°C. After washing in PBS, cells were incubated with appropriate secondary antibodies (Alexa Fluor 488-conjugated anti-rabbit IgG or Alexa Fluor 594-conjugated anti-mouse IgG) for 2 h at room temperature. In some experiments, cells were stained with the DNA-binding dye for 20 min at room temperature at this point to highlight the nucleus. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was performed after secondary antibody incubation using a kit from Roche. For quantification of cell death, at least five coverslips from independent experiments were examined for each condition. All TH ϩ neurons on a coverslip (100 -200) were counted, together with a random selection of 120 -250 TH Ϫ neurons. All fluorescence images were acquired on a confocal microscope from BioRad (Hercules, CA). Monochrome images (512 ϫ 512 pixels) were pseudocolored and merged with the National Institutes of Health (NIH) Image J software.
Measurement of free or polymerized tubulin in the cell. Free or polymerized tubulin from midbrain neuronal cultures was extracted as described previously (Ren et al., 2005) . Briefly, midbrain neuronal cultures maintained in 3.5 cm dishes in vitro for 14 d were washed twice at 37°C with 1 ml Buffer A containing the following: 0.1 M MES (2-[Nmorpholino]ethanesulfonic acid), pH 6.75, 1 mM MgSO 4 , 2 mM EGTA, 0.1 mM EDTA, and 4 M glycerol. After the cultures were incubated at 37°C for 5 min in 600 l of free tubulin extraction buffer (Buffer A plus 0.1% v/v Triton X-100 and protease inhibitors), the extracts were centrifuged at 37°C for 2 min at 16,000 ϫ g. The supernatant fractions contained free tubulin extracted from the cytosol. The pellet fraction and lysed cells in the culture dish were dissolved in 600 l of 25 mM Tris, pH 6.8, plus 0.5% SDS, and contained tubulin originally in a polymerized state (i.e., as microtubules). Equal amounts of total proteins from free or polymerized tubulin fractions were analyzed by Western blotting with anti-␣-tubulin antibody. The intensity of tubulin bands was quantified from three different experiments with the software NIH imaging.
Results
mGluRIII agonists attenuate the selective toxicity of rotenone on cultured midbrain TH ؉ neurons Our previous study has shown that rotenone exhibits much greater toxicity on TH ϩ neurons than on TH Ϫ neurons in rat embryonic midbrain neuronal cultures (Ren et al., 2005) . To identify neuroprotective agents against the selective toxicity of rotenone on dopaminergic neurons, we treated midbrain neuronal cultures with rotenone (100 nM for 12 h) in the presence or absence of various metabotropic glutamate receptor agonists (all at 100 M for 12.5 h, added 0.5 h before rotenone application). Treated cultures were costained for TH (green), TUNEL (red), and NeuN (blue). Rotenone induced significant apoptosis of TH ϩ neurons, but had much less toxicity on TH Ϫ neurons ( Fig. 1 B) . In addition to the positive TUNEL staining in the nucleus, which signified cell death, TH ϩ neurons treated with rotenone also exhibited prominent segmentation of the processes that was often associated with neuronal death (Park et al., 1996) . The selective toxicity of rotenone on TH ϩ neurons was markedly reduced by L-AP-4, a selective mGluRIII agonist (Fig. 1C) , but not by the selective mGluRI agonist tADA ( Fig. 1 D) or the mGluRII agonist APDC (Fig. 1 E) . The protective effect of L-AP-4 was blocked by the selective mGluRIII antagonist CPPG (40 M for 13 h, added 30 min before L-AP-4) ( Fig. 1 F) . As summarized in Figure 1G , rotenone toxicity on TH ϩ neurons was significantly attenuated only by the selective mGluRIII agonists L-AP-4 and L-SOP ( p Ͻ 0.001; n ϭ 7 coverslips), but not by mGluRI agonists (tADA and DHPG) or mGluRII agonists (APDC and the less selective LCCG). Furthermore, the protective effects of mGluRIII agonists were blocked by the selective mGluRIII antagonists CPPG and MSOP (Fig. 1G ). These mGluRIII antagonists per se had no significant effect on rotenone toxicity, and neither did mGluRI antagonists such as CPCCOEt (100 M) and MPEP (2 M), nor mGluRII antagonists such as EGLU (100 M) or APICA (100 M) (data not shown). When added alone, none of these mGluR agonists or antagonists had any significant toxicity on TH ϩ neurons (data not shown).
We also examined the protective effect of L-AP-4 against various concentrations of rotenone and found that the mGluRIII agonist significantly reduced the toxicity of rotenone from 10 nM to 1 M ( p Ͻ 0.001; n ϭ 7) ( Fig. 1 H) . The protective effect of L-AP-4 against rotenone (100 nM) was dose-dependent, reaching a plateau at 100 M (Fig. 1 I) . Thus, all subsequent experiments used 100 nM rotenone and 100 M L-AP-4.
The protective effect of mGluRIII agonists against rotenone toxicity is dependent on the MAP kinase pathway To study the mechanism underlying the protective effect of mGluRIII agonists, we treated midbrain neuronal cultures with rotenone and L-AP-4 in the absence or presence of various inhibitors that block signaling cascades emanating from the activated mGluRIII receptors. The protective effect of L-AP-4 against rotenone-induced apoptosis of TH ϩ neurons (Fig. 1C) was blocked by the MEK inhibitor 2-(2-amino-3-methoxyphenyl-4 H-1-benzopyran-4-one (PD98059) (20 M for 13 h, added 30 min before L-AP-4) (Fig. 2 A) . This was confirmed by another MEK inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto) butadiene (U0126) (Fig. 2 F) . Both MEK inhibitors significantly abrogated the protective effect of L-AP-4 ( p Ͻ 0.001; n ϭ 5) and had no appreciable toxicity on TH ϩ neurons (Fig. 2C,F ) . To substantiate the involvement of MEK in the protective effect of L-AP-4, we transfected midbrain neuronal cultures with HA-tagged wild-type or dominant-negative MEK1 (Mansour et al., 1994) . When overexpressed in cells, the catalytically inactive MEK1 mutant (K97M) acts dominantly to suppress the function of endogenous MEK (Mansour et al., 1994) . Expression of the dominant-negative construct abolished the protective effect of L-AP-4 ( Fig. 2 E, F ) . In contrast, wild-type MEK1 did not significantly change the protective effect of L-AP-4 ( p Ͼ 0.60 vs rotenone plus L-AP-4; n ϭ 5) (Fig. 2 D, F ) .
On the other hand, inhibition of phospha-tidylinositol-3 (PI-3) kinase by wortmannin (0.5 M for 13 h) did not significantly change the effect of L-AP-4 (Fig. 2F) . Similar results were obtained with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) (10 M for 13 h), another specific inhibitor of PI-3 kinase (data not shown). Blocking PLC with U73122 (1 M for 13 h) did not significantly alter the effect of L-AP-4 (Fig. 2F) . We also examined the involvement of protein kinase A (PKA) by using its activator chlorphenylthio (cpt)-cAMP (50 M for 13 h) or myristoylated PKA inhibitory peptide (myr-PKI; 1 M for 13 h). Neither PKA reagent significantly changed the effect of L-AP-4 (Fig. 2B,F) . Application of PD98059, U0126, wortmannin, LY294002, U73122, cptcAMP, or myr-PKI by itself had no significant toxicity on TH ϩ or TH Ϫ neurons, neither did transfection of wild-type or dominantnegative MEK1 per se (data not shown). Together, these results suggest that activation of mGluRIII attenuates rotenone toxicity through a mechanism dependent on the MAP kinase pathway.
mGluRIII agonists induce rapid and transient activation of the MAP kinase ERK
To examine the impact of mGluRIII agonists on MAP kinase, we treated midbrain neuronal cultures with L-AP-4 and blotted total cell lysates with an antibody that recognizes activated ERK1/2, which are doubly phosphorylated on the Thr-Glu-Tyr motif in the activation loop of the kinases (Payne et al., 1991) . As shown in Figure  3A , L-AP-4 (100 M) induced a rapid activation of ERK1 and ERK2, which returned to the basal levels within 30 min. The amounts of total ERK1/2 were not changed by the treatment. We also examined the dose-response of L-AP-4-induced ERK activation. A 3 min treatment with L-AP-4 at various concentrations activated ERK1/2 in a dose-dependent manner (Fig. 3B) . Because ERK1/2 were efficiently activated in response to 100 M L-AP-4 treatment for 3 min, all subsequent mechanistic studies used this regimen.
To ascertain that L-AP-4-induced ERK activation was mediated selectively by group III metabotropic glutamate receptors, we treated midbrain neuronal cultures with specific mGluRIII antagonists for 30 min before the addition of L-AP-4 (100 M for 3 min). L-AP-4-induced activation of ERK1/2 was completely blocked by the specific mGluRIII antagonist CPPG (40 M) and greatly diminished by another antagonist, MSOP (200 M) (Fig.  3C) . To confirm the effect of L-AP-4, we treated midbrain neuronal cultures with another selective mGluRIII agonist L-SOP. Application of L-SOP (100 M for 3 min) induced strong ERK activation, which was completely blocked by the selective mGlu-RIII antagonist CPPG (40 M) and greatly attenuated by another antagonist MSOP (200 M) (Fig. 3D) . Together, these data showed that activation of group III metabotropic glutamate receptors activated the MAP kinase ERK. mGluRIII-induced ERK activation is dependent on Src, ␤-arrestin 2, and dynamin-mediated endocytosis A previous study in human embryonic kidney 293 (HEK293) cells overexpressing mGluR4, one member of the group III metabotropic glutamate receptors, has indicated the involvement of Src in L-AP-4-induced activation of ERK1/2 (Iacovelli et al., 2004) . To examine whether L-AP-4-induced ERK activation is dependent on Src in midbrain neuronal cultures, we treated the cultures with the selective Src kinase inhibitors PP1 and PP2, or the inactive structural homolog PP3 (all at 20 M) for 30 min before the addition of L-AP-4 (100 M for 3 min). As shown in Figure 4 A, L-AP-4-induced ERK activation was completely blocked by the Src inhibitor PP1 or PP2, but not by the inactive homolog PP3. By themselves, these Src-targeted compounds had no significant effect on ERK. Using an antibody that recognizes activated Src, which is phosphorylated on Tyr 418 or equivalent in the catalytic domain (Cooper and MacAuley, 1988) , we found that L-AP-4 (100 M) also activated Src in a rapid and transient manner similar to that of ERK, reaching a plateau around 2ϳ5 min and diminishing to the basal level at 30 min (Fig. 4 B) . When midbrain neuronal cultures were treated with L-AP-4 for 3 min at various concentrations, a plateau effect was seen at 100 M L-AP-4 (Fig. 4C) . Thus, both the time course and dose-response of L-AP-4-induced Src activation parallel those of ERK1/2 (Fig.  3 A, B) . Group III metabotropic glutamate receptors couple to G i /G o classes of G-proteins (Conn and Pin, 1997) , which normally do not activate Src kinase. An alternative mechanism that may lead to Src activation is mediated by the association of ligand-bound GPCRs with ␤-arrestin, which recruits and activates Src (Lefkowitz and Shenoy, 2005) . To examine this possibility, we transfected midbrain neuronal cultures with siRNA against ␤-arrestin 1 or ␤-arrestin 2 to knock down their expression, respectively. As shown in Figure 4 D, the level of ␤-arrestin 1 or ␤-arrestin 2 was greatly reduced by the corresponding siRNA, but not the other (top two panels). L-AP-4-induced activation of ERK1/2 (third panel) and Src (bottom panel) was blocked by knockdown of ␤-arrestin 2, but not ␤-arrestin 1. The expression level of total ERK1/2 or total Src was unaffected by either siRNA (data not shown). These data suggest that L-AP-4-induced ERK activation, which is downstream of Src, is dependent on ␤-arrestin 2.
␤-arrestin-mediated GPCR signaling relies on clathrindependent endocytosis (Lefkowitz and Shenoy, 2005) , which requires dynamin to pinch off clathrin-coated vesicles (Sever, 2002) . To examine whether mGluRIII-induced ERK activation is dependent on clathrin/dynamin-mediated endocytosis, we treated midbrain neuronal cultures with myr-P4 or the unmyristoylated, membrane-impermeable control peptide of the same sequence (P4). Once inside the cell, the P4 peptide disrupts the binding between dynamin and amphiphysin (Gout et al., 1993) and thus blocks clathrin-dependent endocytosis (Kittler et al., 2000) . As shown in Figure 4 E, myristoylated P4 peptide completely blocked L-AP-4-induced activation of ERK1/2, whereas the unmyristoylated control peptide had no significant effect. Neither peptide affected the expression level of ERK1/2 (data not shown). Together, the above data suggest that mGluRIII agonists activate ERK through clathrin/dynamin-mediated endocytosis of the receptors and ensuing ␤-arrestin 2-dependent activation of Src.
mGluRIII-activated ERK targets cytosolic rather than nuclear substrates
To study the cellular consequence of L-AP-4-induced ERK activation, we examined the subcellular localization of activated ERK1/2, as well as total ERK1/2, in midbrain neuronal cultures treated with L-AP-4 (100 M for 3 min). Interestingly, ERK1/2 activated by L-AP-4 stimulation were largely localized in the cytoplasm and did not translocate to the nucleus (Fig. 5, compare A,  B) . This was in sharp contrast to the rapid nuclear translocation of ERK induced by the activation of ionotropic glutamate receptors with a 3 min treatment of 100 M NMDA plus 100 M AMPA (NϩA) (Fig. 5, compare A, C) . Similar results were obtained when the treated cultures were stained for total ERK, which did not show any significant nuclear translocation in response to L-AP-4 (Fig. 5, compare D, E) but exhibited marked accumulation in the nucleus after the treatment with NMDA plus AMPA (Fig. 5, compare D, F ) . We also used the microtubule-associated protein MAP2 as a marker for the cytosolic compartment. Costaining with anti-MAP2 and anti-phospho-ERK showed that L-AP-4-actived ERK remained in the cytoplasm, with very little in the nucleus (Fig. 5, compare G, H ) , whereas ERK activated by NMDA plus AMPA was prominently translocated into the nucleus (Fig. 5, compare G, I ). This was confirmed by costaining with anti-MAP2 and anti-ERK (Fig. 5J-L) .
To substantiate our findings, we performed subcellular fractionation of midbrain neuronal cultures treated for 3 min with the vehicle control, NϩA, or 100 M L-AP-4. Nuclear and cytosolic fractions as well as total cell lysates were blotted with antiphospho-ERK or anti-ERK. The amount of activated ERK or total ERK in the nuclear fraction was not significantly increased by L-AP-4, but was greatly elevated by NMDA plus AMPA (Fig.  5M, left) . On the other hand, both NϩA and L-AP-4 treatments induced a marked increase of phospho-ERK, but not total ERK, in the cytosolic fraction (Fig. 5M, middle) . When total cell lysates were examined, L-AP-4 and NϩA treatment induced similar increases in activated ERK, but not total ERK (Fig. 5M, right) . Thus, subcellular fractionation studies confirmed the immunostaining results. Both readouts suggest that L-AP-4-activated ERK1/2 target cytosolic rather than nuclear substrates.
mGluRIII agonist attenuates rotenone-or colchicine-induced microtubule depolymerization in an MEK-dependent manner
Because activated ERK may phosphorylate microtubuleassociated proteins and stabilize microtubules (Cassimeris and Spittle, 2001 ), we examined the involvement of microtubules in the protective effect of mGluRIII agonists against rotenone tox- icity, which is dependent on microtubules (Ren et al., 2005) . Midbrain cultures were treated with rotenone (100 nM for 3 h) and costained with anti-TH and anti-␣-tubulin to examine microtubules in TH ϩ and TH Ϫ neurons. Microtubules were strongly depolymerized in response to rotenone in TH ϩ neurons (Fig. 6, compare A, B) , as well as in TH Ϫ neurons (data not shown). Frank dendritic segmentation or retraction was seen in rotenone-treated neurons. Coapplication of L-AP-4 (100 M for 3.5 h, added 0.5 h before rotenone) greatly attenuated rotenoneinduced microtubule depolymerization, as well as dendritic segmentation and retraction (Fig. 6, compare B, C) . The effect of L-AP-4 was abrogated by the MEK inhibitor PD98059 (20 M for 4 h, added 0.5 h before L-AP-4) (Fig. 6, compare C, D) . Similar results were found when we treated the cultures with colchicine (10 M for 3 h) instead of rotenone. Colchicine-induced microtubule depolymerization (Fig. 6 F) was attenuated by L-AP-4 (Fig.  6G) . The rescuing effect of L-AP-4 (Fig. 6G ) was abolished by PD98059 (Fig. 6 H) .
We counted the number of neurons with at least one obvious microtubule (defined operationally by a continuous length of at least 10 m) and calculated the percentage of neurons without any microtubule to quantify the degree of microtubule depolymerization. The situations in TH ϩ neurons and TH Ϫ neurons were essentially the same. Thus, we only showed data on TH ϩ neurons in Figure 6 I. Rotenone completely depolymerized microtubules in 51.8 Ϯ 1.3% of TH ϩ neurons. Coapplication of the mGluRIII agonist L-AP-4 significantly mitigated the effect of rotenone (33.6 Ϯ 1.9%; p Ͻ 0.001; n ϭ 5 coverslips). The effect of L-AP-4 was totally blocked by the MEK inhibitor PD98059 (49.0 Ϯ 2.0%; p Ͼ 0.20 vs rotenone alone; n ϭ 5). Similar results were found with colchicine (Fig. 6 I) . We also used another selective inhibitor of MEK, U0126 (20 M), and obtained similar results as those of PD98059 in experiments using rotenone or colchicine (data not shown). By itself, L-AP-4, PD98059 (Fig. 6 E, I ), or U0126 (data not shown) had no significant effect on microtubules, in comparison with the vehicle control.
To substantiate these results, we measured the amount of free tubulin and polymerized tubulin in midbrain neuronal cultures by gently lysing the neurons at 37°C in a low concentration of detergent (0.1% Triton X-100) to extract free tubulin while not disturbing polymerized tubulin in microtubules. As shown in the top panel of Figure 6 J, the amount of free tubulin was greatly increased in response to rotenone (100 nM for 30 min). L-AP-4 (100 M for 60 min, added 30 min before rotenone) significantly reduced the level of free tubulin. This effect was abolished by the MEK inhibitor PD98059 (20 M for 90 min, added 30 min before L-AP-4). Similar results were obtained with colchicine (Fig. 6 J) . Reciprocal changes in response to these agents were observed in the amount of polymerized tubulin (Fig. 6 J, bottom) . By itself, L-AP-4 or PD98059 had no significant effect on the amount of free tubulin or polymerized tubulin, in comparison to the vehicle control (Fig. 6 J) . We also used U0126 and obtained similar results as those from PD98059 (data not shown). Results from three phospho-ERK1/2 or phospho-Src, respectively. Knockdown of ␤-arrestin 2 but not ␤-arrestin 1 blocked L-AP-4-induced activation of ERK and Src. Similar results were obtained from four independent experiments. E, Midbrain neuronal cultures were treated without or with L-AP-4 (100 M for 3 min). Myristoylated dynamin inhibitory peptide P4 or unmodified P4 (both at 25 M) was added 30 min before and during the L-AP-4 treatment. Total cell lysates were blotted with antibodies against phospho-ERK1/2. L-AP-4-induced ERK activation was blocked by myristoylated dynamin inhibitory peptide, but not by the unmodified P4 peptide, which is membrane impermeable. Similar results were obtained from at least three independent experiments. independent experiments were quantified in Figure 6 K. Together, these two different readouts on the polymerization state of microtubules suggest that activation of mGluRIII attenuates rotenone-or colchicine-induced microtubule depolymerization through an MEK-dependent mechanism.
mGluRIII agonist reduces colchicine toxicity on TH ؉ neurons in an MEK-dependent manner The results presented so far suggest that mGluRIII agonists attenuate rotenone toxicity by stabilizing microtubules against rotenone-induced depolymerization. If so, mGluRIII agonists such as L-AP-4 should also protect against the selective toxicity of colchicine on TH ϩ neurons (Ren et al., 2005) . To test this, we treated midbrain neuronal cultures with or without colchicine (10 M for 12 h) in the absence or presence of L-AP-4 (100 M for 12.5 h, added 0.5 h before colchicine). The selective toxicity of colchicine on TH ϩ neurons (Fig. 7B ) was greatly attenuated by L-AP-4 (Fig. 7C ). This protective effect was abolished by coapplication of the MEK inhibitor PD98059 or U0126 (20 M for 13 h, added 0.5 h before L-AP-4) (Fig. 7 D, G) . To substantiate the involvement of MEK, midbrain neuronal cultures transfected with HA-tagged wild-type or dominant-negative MEK1 were treated with colchicine (10 M for 12 h) and L-AP-4 (100 M for 12.5 h, added 0.5 h before L-AP-4). Expression of dominantnegative MEK1 abolished the protective effect of L-AP-4 (Fig. 7F ) , whereas the wild-type construct had no significant impact (Fig. 7E) . Results from five different experiments were quantified in Figure 7G , which suggests that, through an MEKdependent mechanism, mGluRIII agonists reduce the death of TH ϩ neurons induced by microtubule depolymerization.
The protective effect of L-AP-4 against rotenone toxicity is occluded by Taxol
If the protective effect of L-AP-4 against rotenone-induced apoptosis is mediated through microtubule stabilization, then coapplication of Taxol should occlude the effect of L-AP-4, because both of them would act on the same target. To test this, we treated midbrain neuronal cultures with various combinations of rotenone (100 nM for 12 h), Taxol (10 M for 12.5 h, added 0.5 h before rotenone) and L-AP-4 (100 M for 12.5 h, added 0.5 h before rotenone). Rotenoneinduced apoptosis of TH ϩ neurons (Fig. 8 A) was significantly reduced by Taxol (Fig. 8 B) , L-AP-4 (Fig. 8C) or Taxol plus L-AP-4 (Fig. 8 D) . Application of Taxol (Fig. 8 E) or L-AP-4 alone (data not shown) did not significantly affect the survival of TH ϩ neurons. Results from five separate experiments showed that the effects of L-AP-4 (32.4 Ϯ 1.9%) or Taxol (36.8 Ϯ 1.7%) on rotenone toxicity were similar. The combination of L-AP-4 and Taxol (30.8 Ϯ 2.0%) had an effect similar to the individual agents ( p Ͼ 0.05, among the three conditions) (Fig. 8 F) . Thus, the data suggest that L-AP-4 and Taxol are acting on the same target, microtubules, by stabilizing them against rotenone-induced depolymerization.
Discussion
The present study is based on our previous finding that the microtubule-depolymerizing activity of rotenone plays a critical role in its selective toxicity on dopaminergic neurons (Ren et al., 2005) . Microtubule depolymerization disrupted vesicular transport, which relies on intact microtubules and motor proteins (Goldstein, 2003) . This leads to accumulation of vesicles in the cell body and increased cytosolic concentration of the neurotransmitter leaked from the vesicles (Ren et al., 2005) . In the case of dopaminergic neurons, elevated cytosolic concentration of dopamine causes greater oxidative stress because of dopamine oxidation (Ren et al., 2005) , which seems to explain the selectivity of rotenone toxicity. Thus, microtubule stabilization appears to be an effective strategy to protect against rotenone toxicity on DA neurons.
We found in this study that activation of group III metabotropic glutamate receptors (mGluRIII) attenuated rotenone toxicity by stabilizing microtubules. The protective effect was highly selective among agonists and antagonists of metabotropic glutamate receptors (mGluR); only mGluRIII agonists significantly reduced the selective toxicity of rotenone (Fig. 1) or colchicine (Fig. 7) on midbrain TH ϩ neurons in culture. Many lines of evidence showed that this protective effect was dependent on microtubules. The observation that mGluRIII agonists such as L-AP-4 attenuated the toxicity of two structurally different microtubule-depolymerizing agents, rotenone and colchicine, suggests that the common target is microtubules. This notion is corroborated by the results that the protective effect of L-AP-4 was occluded by the microtubule-stabilizing drug Taxol (Fig. 8) . The direct evidence that L-AP-4 stabilized microtubules against depolymerizing agent such as rotenone or colchicine is provided in Figure 6 . We quantified microtubule depolymerization by directly counting neurons without an obvious microtubule and by measuring the amount of free or polymerized tubulin in the cell (Ren et al., 2005) . Both methods yielded the same conclusion that activation of mGluRIII reduced microtubule depolymerization induced by rotenone or colchicine.
The ability of mGluRIII agonists to attenuate the selective toxicity (Figs. 2, 7 ) and the microtubule-depolymerizing effect (Fig. 6 ) of rotenone or colchicine appears to be dependent on activation of the MAP kinase pathway. We used pharmacological agents and molecular manipulations to demonstrate this point. MEK inhibitors such as PD98059 and U0126 completely blocked the protective effect of L-AP-4 against rotenone (Fig. 2) or colchicine (Fig. 7) . This is substantiated by transfection studies using the dominant-negative MEK1 mutant, which also abolished the protection of L-AP-4 (Figs. 2, 7) . Furthermore, the microtubulestabilizing effect of L-AP-4 against rotenone-or colchicine- 
